Physician profile
Basil Pittenger
NPI 1225013485
$642.75
in general payments reported to CMS, 2019-2025
14 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.53 · 2023: $127 · 2024: $363 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $603 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.23 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $134.58 | 2023-2024 | Repatha, Otezla |
| Boston Scientific Corporation | $112.02 | 2024 | Versacross Access Solution |
| Astrazeneca Pharmaceuticals Lp | $67.02 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $48.04 | 2025 | The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $44.55 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $40.62 | 2024-2025 | Camzyos |
| Lantheus Medical Imaging, INC. | $38.02 | 2024 | |
| Pfizer INC. | $34.57 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $34.49 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $25.92 | 2019-2023 | Xarelto |
| Neurelis, INC. | $18.78 | 2024 | Valtoco |
| Alnylam Pharmaceuticals INC. | $16.96 | 2025 | Amvuttra |
| Edwards Lifesciences Corporation | $15.52 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Allergan, INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basil Pittenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.